Samsunb Bioepis

Bio & Pharma Korean court rules in favor of Samsung Bioepis over Regeneron’s Eylea

A South Korean court on Friday ruled in favor of Samsung Bioepis Co. in a patent dispute against Regeneron Pharmaceuticals Inc., a US pharmaceutical...

Bio & Pharma Korean drugmakers control more than half of European biosimilar market

South Korea’s two leading drugmakers, Celltrion Inc. and Samsung Bioepis Co., have achieved a significant milestone in the European biosimilar...

Bio & Pharma Samsung Bioepis gets EC's approval for Opuviz

South Korea's Samsung Bioepis Co., Samsung Biologics Co.'s fully owned biosimilar subsidiary, and the US-based Biogen said on Tuesday the European C...

Earnings Samsung Bioepis Q1 sales surpass $362 mn in US, Europe

Samsung Bioepis Co. reported that its quarterly overseas sales of key biosimilars exceeded 500 billion won ($362 million), according to figures re...

Bio & Pharma Samsung Bioepis eyes record sales in 2024 after stellar Q3

Samsung Bioepis Co., Samsung Biologics Co.'s fully owned biosimilar subsidiary, is expected to post its best-ever annual revenue this year after sal...

Bio & Pharma Samsung Bioepis leads in Soliris biosimilar market in Europe

STOCKHOLM – Samsung Bioepis Co.'s biosimilar to Soliris for the treatment of patients with rare, life-threatening disease paroxysmal nocturnal...

Bio & Pharma Samsung Bioepis gets OK to sell Stelara biosimilar in Europe

South Korea's Samsung Bioepis has received approval from the European Commission to sell Pyzchiva, a biosimilar of the autoimmune disease Stelara.&n...

Bio & Pharma Samsung Bioepis to supply Hadlima to US government

South Korea’s Samsung Bioepis and the US-based Organon, the local partner company of Samsung group's biopharmaceutical research and developmen...

Bio & Pharma Samsung Bioepis gets FDA OK for its interchangeable biosimilar

Byooviz, a biosimilar of the macular degeneration treatment Lucentis and made by South Korea’s Samsung Bioepis, has received official design...

Bio & Pharma Samsung Bioepis releases Soliris biosimilar in Europe

Samsung Bioepis Co., a biopharmaceutical research and development unit under South Korea's Samsung Group, is rolling out its latest product Epysqli,...

Bio & Pharma Samsung Bioepis to cooperate with Swiss firm Sandoz

Samsung Bioepis Co., a biopharmaceutical research and development unit under South Korea's Samsung Group, announced on Monday that it signed a partn...

Bio & Pharma Samsung Bioepis seeks to buy Biogen biosimilar unit

Samsung Bioepis Co., a biopharmaceutical research and development unit under South Korea’s Samsung Group, seeks to buy a biosimilar business d...

Bio & Pharma Samsung Bioepis enters US market for biosimilars of Humira

South Korea's biopharmaceutical company Samsung Bioepis, which was expected to struggle on the US market for biosimilars of Humira, the world's top-...

Bio & Pharma Samsung Bioepis to enhance biosimilar presence with Epysqli

FRANKFURT – Samsung Bioepis Co., a biopharmaceutical unit of South Korea’s top conglomerate Samsung, is looking to gain ground in the ra...

Bio & Pharma Samsung Bioepis gets approval to sell biosimilar in Europe

South Korea's Samsung Bioepis has received approval in Europe to sell a biosimilar of Soliris, a drug for the treatment of adult and children patien...

Bio & Pharma Samsung Bioepis launches ARMD biosimilar drug in Germany, Canada

Samsung Bioepis Co., a South Korean biosimilar firm, announced on Sunday that it has recently launched a new biosimilar drug called SB11 for the tre...

Bio & Pharma Samsung Bioepis sees greater market for Byooviz eye disease biosimilar

NEW YORK – Samsung Bioepis Co., a biopharmaceutical unit of South Korea’s top conglomerate Samsung, is one step ahead of its rivals in t...

Bio & Pharma Samsung Bioepis’ SB12 shows same clinical effects as Alexion’s Soliris

Samsung Bioepis Co., a biopharmaceutical unit of Samsung Group, said its SB12, a proposed biosimilar to Alexion Pharmaceuticals Inc.’s rare bl...

Rights offerings Samsung Biologics to raise $2.6 bn in rights issue

Samsung Biologics Co., a global contract development and manufacturing organization (CDMO) and a biotech division under the Samsung Group, is set ...

Pharmaceuticals Samsung Bioepis to double biosimilars, may resume Nasdaq listing plans

Samsung Bioepis Co., a biopharmaceutical unit of Samsung Group, plans to double the number of its biosimilar products on sale to 10 by 2025 and acce...

Pharmaceuticals Samsung Bioepis posts $1.26 billion in global biosimilar sales

Samsung Bioepis Co., a biopharmaceutical unit of Samsung Group, said on Friday that sales of its five biosimilar products in global markets, excludi...

Mergers & Acquisitions Samsung buys $2.3 bn Bioepis stake from Biogen to end partnership

Samsung Biologics Co. is acquiring a nearly 50% stake in a biosimilar joint venture with Biogen Inc. from the US biotechnology company for $2.3 bill...

Biosimilars Samsung Bioepis gets FDA approval for Lucentis biosimilar Byooviz

Samsung Bioepis Co., a leading South Korean biopharmaceutical company, has received approval from the US Food and Drug Administration for its Byoovi...

Biosimilars Samsung Bioepis gets nod for sale of ophthalmology biosimilar in Europe

South Korea’s biopharmaceutical company Samsung Bioepis Co. won approval from European authorities for sale of Byooviz, its ophthalmology bios...

Biosimilars Celltrion, Samsung Bioepis anticipate increased biosimilar sales in Europe

South Korean biosimilar companies such as Celltrion Inc. and Samsung Bioepis Co. are likely to see their sales hike by tens of millions of dollars...